

**Table 8.6a**  
**Immunosuppression Use for Induction, 1998 to 2007**  
**Recipients with Kidney-Pancreas Transplants**

	Year of Transplant									
	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
<b>Transplants</b>	972	941	915	891	905	871	881	903	924	862
<b>With Immunosuppression Info</b>	969	935	907	887	899	861	862	891	903	840
<b>Induction Drugs</b>										
ALG	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	13.4%	6.3%	3.0%	2.6%	2.8%	1.9%	2.6%	2.4%	0.7%	1.8%
OKT3	27.8%	15.5%	8.2%	3.6%	1.2%	0.3%	0.9%	0.4%	0.8%	1.2%
Thymoglobulin	0.4%	8.8%	22.9%	28.7%	39.2%	48.8%	44.3%	51.6%	61.5%	52.0%
Zenapax	20.5%	27.1%	21.8%	20.0%	16.4%	8.4%	5.0%	4.5%	5.1%	6.5%
Simulect	8.5%	17.1%	27.1%	31.1%	26.4%	16.0%	12.4%	8.2%	5.1%	5.7%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	7.8%	18.6%	14.8%	11.3%	13.2%
<b>No Induction Drugs Recorded</b>	34.7%	33.7%	26.8%	24.4%	23.5%	20.8%	21.1%	21.2%	18.1%	22.0%

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.